Stocks · News reference
Teva Pharmaceutical Industries Ltd. has acquired the worldwide rights to BXCL501, an investigational sublingual film for the treatment of agitation, from BioXcel Therapeutics for $57.5 million upfront plus contingent payments.
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
In UC, duvakitug maintained high rates of clinical remission, clinical response, and endoscopic improvement at Week 44In CD, duvakitug maintained high rates of endoscopic response, clinical response, and clinical
The global migraine market is projected to grow at a 6% CAGR through 2036, reaching expansion driven by rising prevalence, improved diagnosis rates, and development of novel therapies beyond CGRP inhibitors. Key emerging treatments include PACAP-targeted therapies, TRPA1 antagonists, and next-generation neuromuscular approaches. The market was valued at USD 8.3 billion in 2025 across seven major markets, with the United States leading.
The global brain health supplements market is projected to grow from USD 12.47 billion in 2025 to USD 35.41 billion by 2035, driven by increasing consumer awareness of cognitive wellness, demand for natural ingredients, and e-commerce expansion. North America leads with 43.1% market share, while memory enhancement remains the top application. Key growth factors include aging populations, younger consumers seeking cognitive support, and clinical validation of natural ingredients like Bacopa monnieri and Ginkgo Biloba.